{"DataElement":{"publicId":"2682788","version":"1","preferredName":"Chronic Myelogenous Leukemia Transplantation Time Hematologic Complete Remission Molecular Analysis Remission Ind-3","preferredDefinition":"The indicator that describes whether or not the hematologic complete remission achieved at the time of transplant for chronic myelogenous leukemia was a molecular remission.","longName":"CML_HEM_CR_MOL_IND3","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2682778","version":"1","preferredName":"Chronic Myelogenous Leukemia Transplantation Time Hematologic Complete Remission","preferredDefinition":"The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic; an initial indolent chronic phase is followed by an accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001)._The grafting of tissues from one individual to another or place to place within a single individual._The continuum of experience in which events pass from the future through the present to the past._Pertaining to or related to the blood and blood-forming organs._The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.","longName":"CML_HEM_CR_TRN","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2500393","version":"1","preferredName":"CML","preferredDefinition":"The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic: an initial indolent chronic phase is followed by accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001).  -- 2003","longName":"C3174","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1995DB3E-65B1-6546-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-27","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-27","modifiedBy":"ONEDATA","dateModified":"2006-07-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2682776","version":"1","preferredName":"Transplantation Time Hematologic CR","preferredDefinition":"The grafting of tissues from one individual to another or place to place within a single individual.:the continuum of experience in which events pass from the future through the present to the past.:Pertaining to or related to the blood and blood-forming organs.:The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.","longName":"C15342:C25207:C62780:C4870","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transplantation","conceptCode":"C15342","definition":"Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Time","conceptCode":"C25207","definition":"The continuum of experience in which events pass from the future through the present to the past.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Hematologic","conceptCode":"C62780","definition":"Pertaining to or related to the blood and blood-forming organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A689FF0-42EE-1816-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-18","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-18","modifiedBy":"ONEDATA","dateModified":"2007-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A689FF0-42FF-1816-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-18","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-18","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2682785","version":"1","preferredName":"Chronic Myelogenous Leukemia Molecular Analysis Remission Ind-3","preferredDefinition":"The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic; an initial indolent chronic phase is followed by an accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001)._Techniques for studying or analyzing the genetic composition and mechanisms of living organisms at the molecular level. May refer to the understanding and manipulation of genes (DNA)._An abatement in intensity or degree (as in the manifestations of a disease)._A caDSR representation term that is used to indicate a question with permissible values of yes/no/unknown.","longName":"CML_MOL_RM_IND3","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"15","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"bcr/abl unknown","valueDescription":"BCR-ABL Oncoprotein Unknown","ValueMeaning":{"publicId":"2682786","version":"1","preferredName":"BCR-ABL Oncoprotein Unknown","longName":"2682786","preferredDefinition":"An onco-protein generated from the fusion of Bcr and Abl genes by translocation process between chromosome 9 and 22 (Philadelphia chromosome), in CML (P210) and some ALL (P190).: Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BCR/ABL1 Fusion Protein","conceptCode":"C16325","definition":"A fusion protein encoded by the BCR/ABL1 fusion gene. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A68EEE8-39B0-290D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-18","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A68EEE8-39C9-290D-E044-0003BA3F9857","beginDate":"2007-09-18","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-18","modifiedBy":"ALEYR","dateModified":"2007-09-18","deletedIndicator":"No"},{"value":"No","valueDescription":"No ","ValueMeaning":{"publicId":"2567170","version":"1","preferredName":"No","longName":"2567170","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":"Updated to add NCIt concept relationship. Updated VM Short Name to be the Public ID to be consistent with current convention for VM Short Name - DW 10-03-2022","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A68EEE8-39D5-290D-E044-0003BA3F9857","beginDate":"2007-09-18","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-18","modifiedBy":"ALEYR","dateModified":"2007-09-18","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"2567168","version":"1","preferredName":"Yes","longName":"2567168","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":"12/29/2006 - Updated with NCI Thesaurus definition.","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A68EEE8-39E1-290D-E044-0003BA3F9857","beginDate":"2007-09-18","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-18","modifiedBy":"ALEYR","dateModified":"2007-09-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2716668","version":"1","preferredName":"CML Molecular Analysis Remission Ind-3","preferredDefinition":"The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic: an initial indolent chronic phase is followed by accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001).  -- 2003:Techniques for studying or analyzing the genetic composition and mechanisms of living organisms at the molecular level. May refer to the understanding and manipulation of genes (DNA).:An abatement in intensity or degree (as in the manifestations of a disease).:A caDSR representation term that is used to indicate a question with permissible values of yes/no/unknown.","longName":"C3174:C19770:C18246:C38148","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Molecular Analysis","conceptCode":"C19770","definition":"A laboratory procedure that involves the study of tissues, cells, and fluids using DNA/RNA analysis techniques for the identification of characteristics and abnormalities at the molecular level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Remission","conceptCode":"C18246","definition":"An abatement in intensity or degree (as in the manifestations of a disease).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Yes, No, or Unknown Response","conceptCode":"C38148","definition":"A response or indicator that can have a value of yes, no, or unknown.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"41CCF13A-3ADD-345D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-12-21","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-12-21","modifiedBy":"ONEDATA","dateModified":"2007-12-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A68EE64-123F-23EB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-18","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-18","modifiedBy":"REEVESD","dateModified":"2014-08-17","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"pre_ted_cml_cr_mole_rem","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"At the time of transplantatio","type":"Preferred Question Text","description":"At the time of transplantation, was the type of hematologic complete remission of the chronic myelogenous leukemia also molecular remission (bcr/abl)?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A68F81E-8611-2A3E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-18","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-18","modifiedBy":"KUMMEROA","dateModified":"2021-04-29","changeDescription":". 2021-4-29 ak System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}